Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.
Publication
, Journal Article
Keir, ST; Morton, CL; Billups, C; Smith, MA; Houghton, PJ; Gururangan, S
Published in: Pediatr Blood Cancer
September 2008
VNP40101M is a novel alkylating agent that yields two reactive compounds (a chloroethylating species and methylisocyanate) and has demonstrated activity against a wide spectrum of tumor xenografts. VNP40101M was tested against an in vivo panel of five pediatric brain tumor xenografts at a dose of 18 mg/kg/day administered for 5 days. O-6-methylguanine-DNA methyltransferase (MGMT) levels of xenografts were assessed by Western blot analysis. Only one xenograft (GBM2), which lacked detectable MGMT expression, demonstrated an objective response to VNP40101M. VNP4010M antitumor activity was observed only in the absence of MGMT expression, with resistance to VNP4010M seen even with low MGMT expression.
Duke Scholars
Published In
Pediatr Blood Cancer
DOI
EISSN
1545-5017
Publication Date
September 2008
Volume
51
Issue
3
Start / End Page
439 / 441
Location
United States
Related Subject Headings
- Treatment Outcome
- Transplantation, Heterologous
- Sulfonamides
- Oncology & Carcinogenesis
- O(6)-Methylguanine-DNA Methyltransferase
- Mice, Inbred Strains
- Mice
- Hydrazines
- Glioma
- Glioblastoma
Citation
APA
Chicago
ICMJE
MLA
NLM
Keir, S. T., Morton, C. L., Billups, C., Smith, M. A., Houghton, P. J., & Gururangan, S. (2008). Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. Pediatr Blood Cancer, 51(3), 439–441. https://doi.org/10.1002/pbc.21620
Keir, Stephen T., Christopher L. Morton, Catherine Billups, Malcolm A. Smith, Peter J. Houghton, and Sridharan Gururangan. “Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.” Pediatr Blood Cancer 51, no. 3 (September 2008): 439–41. https://doi.org/10.1002/pbc.21620.
Keir ST, Morton CL, Billups C, Smith MA, Houghton PJ, Gururangan S. Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Sep;51(3):439–41.
Keir, Stephen T., et al. “Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.” Pediatr Blood Cancer, vol. 51, no. 3, Sept. 2008, pp. 439–41. Pubmed, doi:10.1002/pbc.21620.
Keir ST, Morton CL, Billups C, Smith MA, Houghton PJ, Gururangan S. Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Sep;51(3):439–441.
Published In
Pediatr Blood Cancer
DOI
EISSN
1545-5017
Publication Date
September 2008
Volume
51
Issue
3
Start / End Page
439 / 441
Location
United States
Related Subject Headings
- Treatment Outcome
- Transplantation, Heterologous
- Sulfonamides
- Oncology & Carcinogenesis
- O(6)-Methylguanine-DNA Methyltransferase
- Mice, Inbred Strains
- Mice
- Hydrazines
- Glioma
- Glioblastoma